Loading...
Market
Which milestone will GSK's IDRX-42 achieve in 2025?
2
Resolution / Starting Odds
Phase 2 initiation • 25%
FDA Fast Track designation • 25%
Positive Phase 1 results • 25%
None of the above • 25%
GSK press releases and clinical trial updates
Story
GSK Acquires IDRx for $1 Billion and $150 Million Earnout to Boost IDRX-42 for Gastrointestinal Cancers
Jan 13, 2025, 07:50 AM
GSK has announced its agreement to acquire IDRx, Inc., a clinical-stage biotech company based in Plymouth, Massachusetts, for an upfront payment of $1 billion. The deal, which could reach a total of $1.15 billion including potential milestone payments of up to $150 million, aims to enhance GSK's portfolio in cancer treatments. IDRx is currently developing IDRX-42, a drug in Phase 1 trials targeting gastrointestinal stromal tumors (GIST) and other gastrointestinal cancers. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the early data from IDRX-42, highlighting its ability to address clinically relevant KIT mutations, which are a significant gap in current treatment options. This acquisition aligns with GSK's strategy to address critical patient needs in the oncology space.
View original story
Similar markets
No • 50%
Yes • 50%
Neutral results requiring further study • 25%
Other outcome • 25%
Negative results halting development • 25%
Positive results leading to Phase 2 • 25%
FDA approval • 25%
No significant milestone • 25%
Phase III trial initiation • 25%
Phase II trial completion • 25%
Two • 25%
None • 25%
One • 25%
Three or more • 25%
Phase 2 completion • 25%
Phase 1 completion • 25%
No significant milestone • 25%
Phase 3 completion • 25%
Other strategic move • 25%
Focus on internal development • 25%
Partnership with another biotech • 25%
Another acquisition in oncology • 25%
Approved in UK only • 25%
Approved in UK and EU • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
None • 25%
Drug C • 25%
Drug B • 25%
Drug A • 25%
